目的:由于蛋白质精氨酸甲基转移酶5(PRMT5)在各种肿瘤中异常表达,本研究旨在评估PRMT5与临床病理和预后特征之间的相关性.
方法:电子数据库,包括PubMed,WebofScience,Scopus,ScienceDirect,和Cochrane图书馆一直搜索到2021年7月25日。使用纽卡斯尔-渥太华质量评估量表对符合条件的研究进行了严格评估。计算汇总风险比(HR)和汇总优势比(OR)以评估效果。使用Engauge数字化仪12.1版、STATA15.1版和R4.0.5版获得和分析数据。
结果:共纳入32项原始研究,涵盖15,583例患者。在我们的数据中,表明高PRMT5水平与晚期肿瘤分期显着相关(OR=2.12,95%CI:1.22-3.70,P=.008;I2=80.7%),并且与不良总生存率(HR=1.59,95%CI:1.46-1.73,P<.001;I2=50%)和无进展生存率(HR=1.53,95%CI:1.24-1.88,P001。此外,亚组分析表明,高水平的PRMT5与肝细胞癌等5种癌症的总体生存率低相关,胰腺癌,乳腺癌,胃癌,还有肺癌.
结论:我们首次发现PRMT5是泛癌性的预后生物标志物,而高水平的PRMT5与某些癌症的不良预后相关。
OBJECTIVE: Since protein arginine methyltransferase 5 (
PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between
PRMT5 and clinicopathological and prognostic features.
METHODS: Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library were searched until July 25, 2021. The critical appraisal of the eligible studies was performed using the Newcastle-Ottawa Quality Assessment Scale. Pooled hazard ratios (HR) and pooled odds ratios (OR) were calculated to assess the effect. Engauge Digitizer version 12.1, STATA version 15.1, and R version 4.0.5 were used to obtain and analysis the data.
RESULTS: A total of 32 original studies covering 15,583 patients were included. In our data, it indicated that high level of
PRMT5 was significantly correlated with advanced tumor stage (OR = 2.12, 95% CI: 1.22-3.70, P =.008; I2 = 80.7%) and positively correlated with poor overall survival (HR = 1.59, 95% CI: 1.46-1.73, P < .001; I2 = 50%) and progression-free survival (HR = 1.53, 95% CI: 1.24-1.88, P < .001; I2 = 0%). In addition, sub-group analysis showed that high level of PRMT5 was associated with poor overall survival for such 5 kinds of cancers as hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer.
CONCLUSIONS: For the first time we found
PRMT5 was pan-cancerous as a prognostic biomarker and high level of
PRMT5 was associated with poor prognosis for certain cancers.